AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 34048362 — intervention group
Group type: EXPERIMENTAL
Intervention: Automated prompts to clinical staff to invite patients to NHSHC
Number of subjects: 7564
Study 34048362 — intervention group
Group type: COMPARATOR
Intervention: No Prompt to clinical staff
Number of subjects: 7564
Study 32063462 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacological preventive potential for positive AAA screening
Number of subjects: 25074
Study 32063462 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacological preventive potential for positive PAD screening
Number of subjects: 25074
Study 32063462 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacological preventive potential for combined vascular screening
Number of subjects: 25074
Study 32063462 — intervention group
Group type: EXPERIMENTAL
Intervention: Attendance at vascular screening
Number of subjects: 25074
Study 35677463 — intervention group
Group type: EXPERIMENTAL
Intervention: MRI imaging with a 1.5 TMR scanner and knee joint standard array coil imaging
Number of subjects: 31
Study 35677463 — intervention group
Group type: COMPARATOR
Intervention: Control group (31 outpatients with acute knee joint injury of the same age group)
Number of subjects: 31
Study 34479242 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnesium sulfate (50 mg/kg/single dose)
Number of subjects: 131
Study 34479242 — intervention group
Group type: COMPARATOR
Intervention: Aminophylline (5 mg/kg/dose followed by continuous infusion at 1 mg/kg/hour for 3 hours)
Number of subjects: 131
Study 35920480 — intervention group
Group type: EXPERIMENTAL
Intervention: Flower essences
Number of subjects: 164
Study 35920480 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 164
Study 36621408 — intervention group
Group type: EXPERIMENTAL
Intervention: MenACWY-TT at Month 0 (ACWY1d)
Number of subjects: 802
Study 36621408 — intervention group
Group type: EXPERIMENTAL
Intervention: MenACWY-TT at Months 0 and 2 (ACWY2d)
Number of subjects: 802
Study 36621408 — intervention group
Group type: EXPERIMENTAL
Intervention: MenACWY-TT and PCV13 at Month 0 (Co-Ad)
Number of subjects: 802
Study 36621408 — intervention group
Group type: EXPERIMENTAL
Intervention: PCV13 at Month 0 and MenACWY-TT at Month 2 (PCV13/ACWY)
Number of subjects: 802
Study 36621408 — intervention group
Group type: COMPARATOR
Intervention: MenACWY-TT (1 dose)
Number of subjects: 802
Study 36621408 — intervention group
Group type: EXPERIMENTAL
Intervention: MenACWY-TT (2 doses)
Number of subjects: 802
Study 32966587 — intervention group
Group type: EXPERIMENTAL
Intervention: Mannitol
Number of subjects: 34
Study 32966587 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34
Study 36244640 — intervention group
Group type: COMPARATOR
Intervention: Control group of a trial of medication adherence reminder and symptom self-management intervention
Number of subjects: 117
Study 34406392 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D deficiency group (n = 1190)
Number of subjects: 1887
Study 34406392 — intervention group
Group type: COMPARATOR
Intervention: Vitamin D sufficiency group (n = 686)
Number of subjects: 1887
Study 34406392 — intervention group
Group type: COMPARATOR
Intervention: Overall population
Number of subjects: 1887
Study 32232410 — intervention group
Group type: EXPERIMENTAL
Intervention: NP213 (Novexatin®) applied daily for 28 days
Number of subjects: 0
Study 35279112 — intervention group
Group type: EXPERIMENTAL
Intervention: Opicapone (OPC) 50 mg once daily
Number of subjects: 140
Study 35279112 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 140
Study 33504329 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 110
Study 33504329 — intervention group
Group type: COMPARATOR
Intervention: Sevoflurane
Number of subjects: 110
Study 616120954 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravitreal aflibercept (IAI) 2mg every 4 weeks (2q4)
Number of subjects: 2457
Study 616120954 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranibizumab 0.5mg every 4 weeks (Rq4)
Number of subjects: 2457
Study 616120954 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravitreal aflibercept (IAI) 2mg every 8 weeks (2q8)
Number of subjects: 2457
Study 34117549 — intervention group
Group type: EXPERIMENTAL
Intervention: Improved cook stoves
Number of subjects: 0
Study 34117549 — intervention group
Group type: COMPARATOR
Intervention: Traditional cook stoves
Number of subjects: 0
Study 35139410 — intervention group
Group type: EXPERIMENTAL
Intervention: HAF Toothpaste (1000 and 1450 ppmF)
Number of subjects: 610
Study 35139410 — intervention group
Group type: EXPERIMENTAL
Intervention: HAF Toothpaste (1450 ppmF)
Number of subjects: 610
Study 35139410 — intervention group
Group type: COMPARATOR
Intervention: Traditional Fluoridated Toothpaste
Number of subjects: 610
Study 33921105 — intervention group
Group type: EXPERIMENTAL
Intervention: Feel‐Breathe device (FBG)
Number of subjects: 20
Study 33921105 — intervention group
Group type: EXPERIMENTAL
Intervention: Oronasal breathing without FB (ONBG)
Number of subjects: 20
Study 33921105 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 20
Study 33066233 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-aminosalicylic acid (5-ASA) therapy
Number of subjects: 16
Study 33066233 — intervention group
Group type: EXPERIMENTAL
Intervention: Fecal microbiota transplantation (FMT)
Number of subjects: 16
Study 33066233 — intervention group
Group type: EXPERIMENTAL
Intervention: FMT
Number of subjects: 16
Study 34551678 — intervention group
Group type: EXPERIMENTAL
Intervention: TDF/FTC + RAL (400 mg b.d.)
Number of subjects: 60
Study 34551678 — intervention group
Group type: EXPERIMENTAL
Intervention: TDF/FTC + DTG
Number of subjects: 60
Study 34551678 — intervention group
Group type: EXPERIMENTAL
Intervention: TDF/FTC + EVG/c
Number of subjects: 60
Study 32049269 — intervention group
Group type: EXPERIMENTAL
Intervention: Permissive hypotension (MAP target 60-65 mm Hg)
Number of subjects: 2463
Study 32049269 — intervention group
Group type: COMPARATOR
Intervention: Usual care (vasopressors at the discretion of treating clinicians)
Number of subjects: 2463
Study 35858181 — intervention group
Group type: EXPERIMENTAL
Intervention: S-CHOP (Ripertamab combined with CHOP)
Number of subjects: 364
Study 35858181 — intervention group
Group type: COMPARATOR
Intervention: R-CHOP (Rituximab combined with CHOP)
Number of subjects: 364
Study 35858181 — intervention group
Group type: EXPERIMENTAL
Intervention: S-CHOP
Number of subjects: 364
Study 35858181 — intervention group
Group type: COMPARATOR
Intervention: R-CHOP
Number of subjects: 364
Study 34159380 — intervention group
Group type: EXPERIMENTAL
Intervention: Nsp2-interacting proteins identified through affinity purification mass spectrometry (AP-MS) and stable isotope labeling by amino acids in cell culture (SILAC)
Number of subjects: 0
Study 34159380 — intervention group
Group type: EXPERIMENTAL
Intervention: Nsp2
Number of subjects: 0
Study 34159380 — intervention group
Group type: EXPERIMENTAL
Intervention: Bio-layer interferometry (BLI) assay
Number of subjects: 0
Study 35032700 — intervention group
Group type: EXPERIMENTAL
Intervention: Affect Management Treatment (AMT)
Number of subjects: 52
Study 35032700 — intervention group
Group type: COMPARATOR
Intervention: Cognitive Behavioral Therapy (CBT)
Number of subjects: 52
Study 32200433 — intervention group
Group type: EXPERIMENTAL
Intervention: Olfaction rehabilitation (OPRAT)
Number of subjects: 33
Study 32200433 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 33
Study 34383632 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic Training (AT)
Number of subjects: 45
Study 34383632 — intervention group
Group type: COMPARATOR
Intervention: Control (CO)
Number of subjects: 45
Study 34383632 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance Training (RT)
Number of subjects: 45
Study 33980690 — intervention group
Group type: EXPERIMENTAL
Intervention: Target LDL cholesterol of <70 mg/dL
Number of subjects: 2860
Study 33980690 — intervention group
Group type: COMPARATOR
Intervention: Target LDL cholesterol of 100 ± 10 mg/dL
Number of subjects: 2860
Study 33980690 — intervention group
Group type: EXPERIMENTAL
Intervention: Target LDL cholesterol of <70 mg/dL (in patients with diabetes)
Number of subjects: 2860
Study 33980690 — intervention group
Group type: COMPARATOR
Intervention: Target LDL cholesterol of 100 ± 10 mg/dL (in patients with diabetes)
Number of subjects: 2860
Study 33980690 — intervention group
Group type: EXPERIMENTAL
Intervention: Target LDL cholesterol of <70 mg/dL (newly diagnosed diabetes)
Number of subjects: 2860
Study 33980690 — intervention group
Group type: COMPARATOR
Intervention: Target LDL cholesterol of 100 ± 10 mg/dL (newly diagnosed diabetes)
Number of subjects: 2860
Study 32867047 — intervention group
Group type: EXPERIMENTAL
Intervention: 29 mL of vinegar and 451 mL of water
Number of subjects: 22
Study 32867047 — intervention group
Group type: EXPERIMENTAL
Intervention: 39 g of sucrose and 441 mL of water
Number of subjects: 22
Study 32867047 — intervention group
Group type: EXPERIMENTAL
Intervention: 29 mL of vinegar and 39 g of sucrose and 412 mL of water
Number of subjects: 22
Study 32867047 — intervention group
Group type: COMPARATOR
Intervention: 480 mL of water alone
Number of subjects: 22
Study 34713704 — intervention group
Group type: EXPERIMENTAL
Intervention: Dobutamine
Number of subjects: 192
Study 34713704 — intervention group
Group type: COMPARATOR
Intervention: Milrinone
Number of subjects: 192
Study 34713704 — intervention group
Group type: EXPERIMENTAL
Intervention: AMICS
Number of subjects: 192
Study 34713704 — intervention group
Group type: COMPARATOR
Intervention: Non-AMICS
Number of subjects: 192
Study 33279104 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcutaneous electrical nerve stimulation (TENS) at 10 Hz for 45 minutes followed by 30 minutes of aerobic exercise
Number of subjects: 8
Study 33279104 — intervention group
Group type: COMPARATOR
Intervention: Placebo TENS followed by 30 minutes of aerobic exercise
Number of subjects: 8
Study 34023514 — intervention group
Group type: EXPERIMENTAL
Intervention: Spiral thread sutures
Number of subjects: 200
Study 34023514 — intervention group
Group type: COMPARATOR
Intervention: Conventional sutures (0-Vicryl)
Number of subjects: 200
Study 35611970 — intervention group
Group type: EXPERIMENTAL
Intervention: Afirma GSC (suspicious result)
Number of subjects: 343
Study 35611970 — intervention group
Group type: EXPERIMENTAL
Intervention: Afirma GSC (benign result)
Number of subjects: 343
Study 35611970 — intervention group
Group type: EXPERIMENTAL
Intervention: ThyroSeq v3 (positive result)
Number of subjects: 343
Study 35611970 — intervention group
Group type: EXPERIMENTAL
Intervention: ThyroSeq v3 (negative result)
Number of subjects: 343
Study 32581204 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg of esomeprazole twice daily (BD)
Number of subjects: 37
Study 32581204 — intervention group
Group type: COMPARATOR
Intervention: 40 mg of esomeprazole once daily (OD)
Number of subjects: 37
Study 36209520 — intervention group
Group type: EXPERIMENTAL
Intervention: High explicit language
Number of subjects: 498
Study 36209520 — intervention group
Group type: COMPARATOR
Intervention: Low explicit language
Number of subjects: 498
Study 34113957 — intervention group
Group type: EXPERIMENTAL
Intervention: EPA-rich oil (360 mg DHA/d and 900 mg EPA/d)
Number of subjects: 310
Study 34113957 — intervention group
Group type: EXPERIMENTAL
Intervention: DHA-rich oil (900 mg DHA/d and 270 mg EPA/d)
Number of subjects: 310
Study 34113957 — intervention group
Group type: COMPARATOR
Intervention: Placebo (3000 mg/d refined olive oil)
Number of subjects: 310
Study 34323290 — intervention group
Group type: EXPERIMENTAL
Intervention: Fremanezumab monthly (225 mg at baseline, week 4, and week 8)
Number of subjects: 357
Study 34323290 — intervention group
Group type: EXPERIMENTAL
Intervention: Fremanezumab quarterly (675 mg at baseline, placebo at weeks 4 and 8)
Number of subjects: 357
Study 34323290 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 357
Study 32930088 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioural Therapy (CBT) delivered via 13 out-patient sessions over 160 days
Number of subjects: 1
Study 32930088 — intervention group
Group type: EXPERIMENTAL
Intervention: Person-Centred Experiential Therapy (PCE) delivered via six out-patient sessions over 63 days
Number of subjects: 1
Study 32930088 — intervention group
Group type: COMPARATOR
Intervention: Baseline assessment phase (A; 28 days; three sessions)
Number of subjects: 1
Study 32930088 — intervention group
Group type: COMPARATOR
Intervention: Follow-up period (99 days)
Number of subjects: 1
Study 35233755 — intervention group
Group type: EXPERIMENTAL
Intervention: Trastuzumab + chemotherapy
Number of subjects: 0
Study 35233755 — intervention group
Group type: COMPARATOR
Intervention: Trastuzumab monotherapy
Number of subjects: 0
Study 35233755 — intervention group
Group type: COMPARATOR
Intervention: Trastuzumab + chemotherapy vs trastuzumab monotherapy
Number of subjects: 0
Study 33385220 — intervention group
Group type: EXPERIMENTAL
Intervention: Observational studies
Number of subjects: 0
Study 33577365 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-term androgen deprivation therapy (LT-ADT) with calcium and vitamin D supplementation (CalVitD) (500 mg of Calcium BID + 400 IU of Vitamin D3 BID)
Number of subjects: 230
Study 33577365 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium and vitamin D supplementation (CalVitD)
Number of subjects: 230
Study 35369896 — intervention group
Group type: EXPERIMENTAL
Intervention: Food-based nutrition counselling and education intervention
Number of subjects: 10
Study 35111703 — intervention group
Group type: EXPERIMENTAL
Intervention: PHiD‐CV (single dose)
Number of subjects: 292
Study 35111703 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 292
Study 33008770 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin (1000 mg/day)
Number of subjects: 424
Study 33008770 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 424
Study 35291434 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous caffeine (10 mg/Kg)
Number of subjects: 18
Study 35291434 — intervention group
Group type: COMPARATOR
Intervention: Intravenous normal saline (placebo)
Number of subjects: 18
Study 36164137 — intervention group
Group type: EXPERIMENTAL
Intervention: Isa-Kd (Isatuximab 10 mg/kg IV weekly for 4 weeks, then every 2 weeks; Carfilzomib 20/56 mg/m2 twice weekly, 3/4 weeks)
Number of subjects: 302
Study 36164137 — intervention group
Group type: EXPERIMENTAL
Intervention: Isa-Kd
Number of subjects: 302
Study 34047291 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-level laser therapy (LLLT) at 810 nm, 200 MW constant power, 30s irradiation time, energy dose of 6 J
Number of subjects: 20
Study 34047291 — intervention group
Group type: COMPARATOR
Intervention: Sham laser treatment
Number of subjects: 20
Study 34695227 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaccinated individuals
Number of subjects: 0
Study 34695227 — intervention group
Group type: COMPARATOR
Intervention: Previously infected individuals
Number of subjects: 0
Study 34695227 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall population seroprevalence
Number of subjects: 0
Study 33642694 — intervention group
Group type: EXPERIMENTAL
Intervention: Hybrid assistive limb treatment
Number of subjects: 20
Study 33642694 — intervention group
Group type: COMPARATOR
Intervention: Conventional training
Number of subjects: 20
Study 32800792 — intervention group
Group type: EXPERIMENTAL
Intervention: Football Fitness group (FFG, n = 46)
Number of subjects: 68
Study 32800792 — intervention group
Group type: COMPARATOR
Intervention: Control group (CON, n = 22)
Number of subjects: 68
Study 33971037 — intervention group
Group type: EXPERIMENTAL
Intervention: Elobixibat plus 1-L PEG-Asc solution (group A)
Number of subjects: 210
Study 33971037 — intervention group
Group type: COMPARATOR
Intervention: Sodium picosulfate plus 1-L PEG-Asc solution (group B)
Number of subjects: 210
Study 32776853 — intervention group
Group type: EXPERIMENTAL
Intervention: Protocolized sedation management (intervention arm)
Number of subjects: 2271
Study 32776853 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control arm)
Number of subjects: 2271
Study 616037868 — intervention group
Group type: EXPERIMENTAL
Intervention: B&L Akreos AO60
Number of subjects: 20
Study 616037868 — intervention group
Group type: EXPERIMENTAL
Intervention: AMO Tecnis ZCB00
Number of subjects: 20
Study 35238311 — intervention group
Group type: EXPERIMENTAL
Intervention: Levosimendan preconditioning
Number of subjects: 258
Study 35238311 — intervention group
Group type: COMPARATOR
Intervention: Dobutamine (Control)
Number of subjects: 258
Study 35700157 — intervention group
Group type: EXPERIMENTAL
Intervention: Edaravone
Number of subjects: 0
Study 35700157 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 33979752 — intervention group
Group type: EXPERIMENTAL
Intervention: FreeStyle Navigator II subcutaneous CGM system from Abbott
Number of subjects: 94
Study 33036588 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrocortisone dose A (20 mg/10 mg)
Number of subjects: 10
Study 33036588 — intervention group
Group type: COMPARATOR
Intervention: Hydrocortisone dose C (10 mg/5 mg)
Number of subjects: 10
Study 33036588 — intervention group
Group type: EXPERIMENTAL
Intervention: Night-time serum cortisone levels
Number of subjects: 10
Study 33036588 — intervention group
Group type: EXPERIMENTAL
Intervention: Total urinary cortisol metabolites
Number of subjects: 10
Study 35803549 — intervention group
Group type: EXPERIMENTAL
Intervention: Opioid-sparing (OS) postoperative pain protocol
Number of subjects: 78
Study 35803549 — intervention group
Group type: COMPARATOR
Intervention: Traditional opioid-based (OB) postoperative pain protocol
Number of subjects: 78
Study 33819072 — intervention group
Group type: COMPARATOR
Intervention: Oxycodone (5 mg)
Number of subjects: 81
Study 33819072 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketorolac (10 mg)
Number of subjects: 81
Study 33819072 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 81
Study 83103622 — intervention group
Group type: EXPERIMENTAL
Intervention: Psoradrate (0.1% dithranol with 17% urea)
Number of subjects: 40
Study 83103622 — intervention group
Group type: COMPARATOR
Intervention: Dithrocream (0.25% dithranol in vanishing cream)
Number of subjects: 40
Study 35164859 — intervention group
Group type: COMPARATOR
Intervention: Model-oriented group (n = 10)
Number of subjects: 36
Study 35164859 — intervention group
Group type: COMPARATOR
Intervention: Differential Learning group (n = 11)
Number of subjects: 36
Study 35164859 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 10)
Number of subjects: 36
Study 33359250 — intervention group
Group type: EXPERIMENTAL
Intervention: Osteoarthritis
Number of subjects: 258696
Study 33359250 — intervention group
Group type: COMPARATOR
Intervention: No osteoarthritis (Control)
Number of subjects: 258696
Study 35178150 — intervention group
Group type: EXPERIMENTAL
Intervention: Water treatment (household chlorination with sodium hypochlorite)
Number of subjects: 0
Study 35178150 — intervention group
Group type: EXPERIMENTAL
Intervention: Handwashing (with soap)
Number of subjects: 0
Study 35178150 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined intervention (water treatment and handwashing)
Number of subjects: 0
Study 35178150 — intervention group
Group type: COMPARATOR
Intervention: Control (customary practices)
Number of subjects: 0
Study 32560898 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 36471204 — intervention group
Group type: EXPERIMENTAL
Intervention: BGS-7 spacer
Number of subjects: 54
Study 36471204 — intervention group
Group type: COMPARATOR
Intervention: PEEK cage
Number of subjects: 54
Study 34225380 — intervention group
Group type: EXPERIMENTAL
Intervention: Tubeless technique
Number of subjects: 63
Study 34225380 — intervention group
Group type: COMPARATOR
Intervention: Conventional technique
Number of subjects: 63
Study 34719064 — intervention group
Group type: EXPERIMENTAL
Intervention: Personalized visual triggers during fMRI scans
Number of subjects: 10
Study 34719064 — intervention group
Group type: EXPERIMENTAL
Intervention: Subject-specific trigger images
Number of subjects: 10
Study 34719064 — intervention group
Group type: EXPERIMENTAL
Intervention: MRI methodology specific for urologic use
Number of subjects: 10
Study 33475184 — intervention group
Group type: EXPERIMENTAL
Intervention: C. zeylanicum (0.5 mg/mL)
Number of subjects: 36
Study 33475184 — intervention group
Group type: EXPERIMENTAL
Intervention: Nystatin (100,000 IU/mL)
Number of subjects: 36
Study 32151146 — intervention group
Group type: EXPERIMENTAL
Intervention: DriSti intervention (partly tablet-administered, interactive)
Number of subjects: 3182
Study 35134317 — intervention group
Group type: EXPERIMENTAL
Intervention: Microwave ablation (MWA)
Number of subjects: 34
Study 35134317 — intervention group
Group type: COMPARATOR
Intervention: Uterine artery embolization (UAE)
Number of subjects: 34
Study 32892392 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-layer uterine closure
Number of subjects: 2292
Study 32892392 — intervention group
Group type: EXPERIMENTAL
Intervention: Double-layer uterine closure
Number of subjects: 2292
Study 35555498 — intervention group
Group type: EXPERIMENTAL
Intervention: 3D brachial plexus board model
Number of subjects: 12
Study 35555498 — intervention group
Group type: COMPARATOR
Intervention: Drawing the brachial plexus utilizing the online resource, Draw It to Know It
Number of subjects: 12
Study 32139102 — intervention group
Group type: EXPERIMENTAL
Intervention: Negative Pressure Wound Therapy (NPWT) with irrigation at 30 cc per hour
Number of subjects: 150
Study 32139102 — intervention group
Group type: COMPARATOR
Intervention: Negative Pressure Wound Therapy (NPWT) without irrigation
Number of subjects: 150
Study 32139102 — intervention group
Group type: EXPERIMENTAL
Intervention: Negative Pressure Wound Therapy (NPWT) with irrigation
Number of subjects: 150
Study 35501772 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT) program
Number of subjects: 91
Study 35501772 — intervention group
Group type: COMPARATOR
Intervention: No treatment (Control)
Number of subjects: 91
Study 32664809 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-centered multi-component hospital-to-home (H2H) program
Number of subjects: 32
Study 32664809 — intervention group
Group type: COMPARATOR
Intervention: Guideline-based asthma care without H2H program
Number of subjects: 32
Study 35046704 — intervention group
Group type: EXPERIMENTAL
Intervention: Aggressive temperature management (Group A)
Number of subjects: 98
Study 35046704 — intervention group
Group type: COMPARATOR
Intervention: Routine temperature management (Group C)
Number of subjects: 98
Study 34814933 — intervention group
Group type: EXPERIMENTAL
Intervention: Tenofovir/lamivudine (TDF/3TC)
Number of subjects: 24